Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228314 | 1.00 | POLB (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL10331118 | 1.00 | POLB (0.56) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL13576805 | 0.93 | POLB (0.54) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL1970390 | 0.92 | POLB (0.57) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL1970398 | 0.92 | POLB (0.57) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL15329281 | 0.91 | POLB (0.52) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL9328007 | 0.89 | POLB (0.55) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL31651546 | 0.89 | POLB (0.51) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL4303303 | 0.89 | POLB (0.57) | POLBLMNAPDE3ACACNA1FALB | |
| SCHEMBL5038295 | 0.89 | POLB (0.62) | POLBLMNAPDE3ACACNA1FALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20250313840-A1 | MUCIN-5B (MUC5B) TARGETED SIRNA AND ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-09 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | claimed |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-08-07 | — | — | US | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-120077136-A | SiRNA and drug for inhibiting Amyloid Precursor Protein (APP) gene expression and application thereof | 广州必贝特医药股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-120077134-A | APOC 3-targeted polynucleic acid molecule and application thereof | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2022231999-A1 | TRANSMEMBRANE PROTEASE, SERINE 6 (TMPRSS6) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022119873-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022087329-A1 | MUCIN 5B (MUC5B) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087041-A1 | METHODS AND COMPOSITIONS FOR TREATING PRIMARY HYPEROXALURIA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022076291-A1 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| WO-2022066847-A1 | DIPEPTIDYL PEPTIDASE 4 (DPP4) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| US-20210332365-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2021-10-28 | — | — | US | claimed |
| EP-3837366-A1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| WO-2020036862-A9 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | claimed |
| WO-2020036862-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | POLB 431/4885LMNA 242/4885PDE3A 3280/4885 |
| US-20210332365-A1 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | HAVCR2, EIF2AK2, ADAR | POLB 139/4885LMNA 2089/4885PDE3A 3147/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | POLB 712/4885LMNA 240/4885PDE3A 1228/4885 |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | F13B, F13A1, F12 | POLB 95/4885LMNA 350/4885PDE3A 2491/4885 |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | APOB, APOL1, NOP10 | POLB 163/4885LMNA 114/4885PDE3A 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.